Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study

Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study

Abstract This was a multicenter, single-arm, open-label, phase Ib/II study (NCT04255576), aimed to evaluate the efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone (GCTB). JMT103 (2 mg/kg) was administered subcutaneously every four weeks, wi...

Full description

Bibliographic Details
Main Authors: Hairong Xu, Yong Zhou, Li Liang, Jingnan Shen, Wangjun Yan, Jin Wang, Jianmin Li, Xiaojing Zhang, Gang Huang, Wenzhi Bi, Zheng Guo, Yanbin Xiao, Jianhua Lin, Weitao Yao, Zhichao Tong, Wenxian Zhou, Guochuan Zhang, Zhaoming Ye, Dong Wang, Jilong Yang, Zhengfu Fan, Caigang Liu, Guofan Qu, Qing Zhang, Feng Wei, Weifeng Liu, Chongqi Tu, Hong Li, Jing Yuan, Xiaohui Niu
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-53686-4

Internet

https://doi.org/10.1038/s41467-024-53686-4

Similar Items